Arvinas Stock Price, News & Analysis

Arvinas, Inc. (Nasdaq: ARVN) reported its Q2 2022 financial results, highlighting revenues of $31.3 million, a significant increase from $5.5 million in Q2 2021. The net loss rose to $70.0 million from $50.3 million, attributed to higher R&D and administrative costs. The company plans to initiate pivotal trials for ARV-471 and bavdegalutamide in metastatic cancers, with the Phase 3 trial set for 2H 2023. As of June 30, 2022, cash and equivalents were $1,347.7 million, sufficient to fund operations beyond 2024.

Arvinas, Inc. (Nasdaq: ARVN) has appointed John Northcott as the Chief Commercial Officer (CCO), a new role in the company. Northcott brings extensive experience from notable companies like Nektar Therapeutics and Pharmacyclics, where he successfully led product development and commercialization. CEO John Houston expressed confidence that Northcott's expertise will significantly aid in advancing Arvinas' drug pipeline, especially as the company prepares for late-stage development. Arvinas specializes in therapies that target and degrade disease-causing proteins, aiming to improve outcomes in cancer treatments.

Arvinas, a clinical-stage biotechnology firm listed on Nasdaq under the symbol ARVN, announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference scheduled for June 13 at 4:20 p.m. ET. The event will feature a fireside chat with the company's management in Rancho Palos Verdes, California. A live audio webcast will be available on the company's website. Arvinas focuses on developing therapies that degrade disease-causing proteins, utilizing its proprietary PROTAC® technology, with ongoing clinical programs targeting prostate and breast cancer.

Arvinas, a clinical-stage biotechnology company, announced a $25,000 Early Career Research Award to honor 20 years of targeted protein degradation. This award aims to recognize innovative research efforts in the field, with nominations open until August 1, 2022. The winner will be presented at the 5th Annual Targeted Protein Degradation Summit in October 2022. Arvinas emphasizes its commitment to advancing biotechnology through innovative therapies that degrade disease-causing proteins.

GNS Healthcare announced a collaboration with Arvinas (ARVN) aimed at accelerating drug development for neurodegenerative diseases. By utilizing GNS' Gemini Virtual Patient models, Arvinas seeks to gain insights into disease progression, enhancing drug candidate selection and clinical trial efficiency. With over six million new diagnoses of Alzheimer's, Parkinson's, and Huntington's diseases annually in the U.S., this partnership intends to improve patient outcomes through targeted protein degradation therapies. Both companies emphasize a commitment to advancing treatment options for these chronic conditions.

Arvinas, Inc. (Nasdaq: ARVN) reported its Q1 2022 financial results, highlighting a productive quarter with plans for three pivotal clinical trials in 2022. Revenue surged to $24.2 million, up from $5.5 million in Q1 2021, driven by collaborations, particularly the ARV-471 program. However, net loss increased to $63.4 million from $41.0 million, primarily due to rising R&D and administrative costs. Cash reserves decreased to $1.43 billion. Key milestones include ongoing trials for ARV-471 and bavdegalutamide while preparing for potential FDA discussions.

Arvinas, a clinical-stage biotechnology company, announced participation in the Bank of America Securities 2022 Healthcare Conference on May 10 at 7:00 p.m. ET in Las Vegas. The event will feature a fireside chat with management, and a live audio webcast will be available on the company's website. Arvinas specializes in targeted protein degradation therapies, utilizing its proprietary PROTAC® Discovery Engine platform. The company has three clinical-stage programs focused on various cancers, including prostate and breast cancer.

Arvinas, a clinical-stage biotechnology company, announced participation in two virtual investor conferences. The first is the Cowen & Co. 42nd Annual Health Care Conference on March 7, featuring a fireside chat with Chief Scientific Officer Ian Taylor. The second event is the Guggenheim Targeted Protein Degradation Day on March 16, also with Taylor. Arvinas focuses on developing therapies that degrade disease-causing proteins using its PROTAC technology. The company has three clinical-stage programs targeting advanced prostate and breast cancer.

Arvinas, Inc. (Nasdaq: ARVN) reported its financial results for Q4 and the full year 2021, highlighting significant advancements in its drug development pipeline and a strong collaboration with Pfizer.

The company reported revenues of $46.7 million for 2021, up from $21.8 million in 2020, primarily driven by the ARV-471 collaboration. However, the net loss increased to $191 million due to rising R&D costs of $180.4 million. Key milestones are anticipated in 2022 for both ARV-471 and bavdegalutamide, including pivotal trials.